Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500 mg for 4 weeks in treating chronic bacterial prostatitis

References

• Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother 2007;8:1667-74
   PubMed Web of Science ®Google Scholar
• Naber KG, Sorgel F. Antibiotic therapy – rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35:331-5
   PubMed Web of Science ®Google Scholar
• Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008;68:535-65
   PubMed Web of Science ®Google Scholar
• Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19
   PubMed Web of Science ®Google Scholar
• Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true?. Am J Med 1999;106:327-34
   PubMed Web of Science ®Google Scholar
• Naber KG, Busch W, Focht J. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. Int J Antimicrob Agents 2000;14:143-9
   PubMed Web of Science ®Google Scholar
• Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62:537-41
   PubMed Web of Science ®Google Scholar
• Naber KG. Management of bacterial prostatitis: what's new?. BJU Int 2008;101(Suppl 3):7-10
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000;44:2046-51
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-7
   Google Scholar
• Poole M, Anon J, Paglia M, et al. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg 2006;134:10-17
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25:1001-10
   PubMed Web of Science ®Google Scholar
• Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008;71:17-22
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Moellering Jr RC, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy 2008. Antimicrobial Therapy, 2008
   Google Scholar
• Naber KG, Weidner W. Chronic prostatitis-an infectious disease?. J Antimicrob Chemother 2000;46:157-61
   PubMed Web of Science ®Google Scholar
• Soto SM, Smithson A, Martinez JA, et al. Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance. J Urol 2007;177:365-8
   PubMed Web of Science ®Google Scholar
• Roberts RO, Lieber MM, Bostwick DG, et al. A review of clinical and pathological prostatitis syndromes. Urology 1997;49:809-21
   PubMed Web of Science ®Google Scholar
• Terai A, Yamamoto S, Mitsumori K, et al. Escherichia coli virulence factors and serotypes in acute bacterial prostatitis. Int J Urol 1997;4:289-94
   PubMedGoogle Scholar
• Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire, France: World Medical Association. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html [Last accessed 23 July 2009]
   Google Scholar
• Guideline for Good Clinical Practice. London, England: European Medicines Agency, 2002. Available at: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf [Last accessed 23 July 2009]
   Google Scholar
• Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369-75
   Google Scholar
• Shao J, Zhong B. Last observation carry-forward and last observation analysis. Stat Med 2003;22:2429-41
   PubMed Web of Science ®Google Scholar